TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03065023
Drug: MK-4621
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
Study: NCT00705432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
Study: NCT02454387
Drug: Placebo Part A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers
Study: NCT02454387
Drug: ONO-4474 Part A2
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers
Study: NCT02454387
Drug: Placebo Part A2
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers
Study: NCT02454387
Drug: Placebo Part B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers
Study: NCT02454387
Drug: Placebo Part C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers
Study: NCT02454387
Drug: Placebo Part D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers
Study: NCT02331680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02185131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
Study: NCT00283517
Drug: antipsychotics
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT03722238
Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Study: NCT02730975
Drug: AA reduced dose-fat diet (B)
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
Study: NCT03107871
Drug: Simple Syrup
Normalized name: Simple syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
Study: NCT01493154
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
Study: NCT00012350
Drug: FTI
Normalized name: Keftid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01293734
Drug: Theophylline Sustained-release Tablets and budesonide suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
Study: NCT00618046
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00740129
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg intravenous infusion once
Study: NCT02706015
Drug: Cefaliv® & Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
Study: NCT02706015
Drug: Neosaldina® & Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
Study: NCT02158546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT00860860
Drug: TF2
Normalized name: PROSOURCE TF20 LIQUID,ORAL,60ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: TF2: 75-300 mg
Study: NCT02057250
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dispensed according to local practice.
Study: NCT03771664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as capsules.
Study: NCT02120898
Drug: Zyclara®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream, brand product.
Study: NCT02120898
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
Study: NCT00831181
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
Study: NCT00649038
Drug: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Normalized name: benazepril hydrochloride / hydrochlorothiazide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/25mg, single dose fed
Study: NCT00649038
Drug: Lotensin HCT® Tablets 20 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/25mg, single dose fed
Study: NCT01635296
Drug: RO5045377
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
Study: NCT01635296
Drug: RO5045377
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
Study: NCT00783068
Drug: GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
Study: NCT00783068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
Study: NCT01119118
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
Study: NCT00483717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) placebo
Study: NCT00417417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline subcutaneously at each treatment visit.
Study: NCT01052337
Drug: anaesthetics: sevofluorane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5%of sevofluorane with air
Study: NCT05023499
Drug: SYMPT-X Glutamine, Oral Powder for Reconstitution
Normalized name: SYMPT-X Glutamine, oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
Study: NCT01652040
Drug: Testosterone Patches
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
Study: NCT00439010
Drug: [123I] AV 39
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00598910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04048356
Drug: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Study: NCT00828009
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT03022318
Drug: carbidopa-levodopa 25-100 mg tablets
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm/group descriptions
Study: NCT00399906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, Once daily, 12 weeks
Study: NCT02281916
Drug: P28GST
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of 100 µg of P28GST within 3 months (one injection per month)
Study: NCT03236636
Drug: HUACHANSU PIAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
Study: NCT04067817
Drug: norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient who was received the treatment of norepinephrine
Study: NCT00734539
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
Study: NCT04000633
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT04948372
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
Study: NCT01378871
Drug: IMTOX-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7.
Study: NCT02366546
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Study: NCT00005068
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005068
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00421928
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo twice a day (BID) during 15 weeks
Study: NCT01301157
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proper quantity twice a day
Study: NCT01301157
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proper quantity twice a day
Study: NCT02892344
Drug: QMF149 150/80 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: QMF149 150/80 μg o.d via Concept1
Study: NCT02892344
Drug: MF 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF 200 μg o.d. via Twisthaler®
Study: NCT01780740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
Study: NCT01376258
Drug: 5ARI
Normalized name: 5-alpha reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: dutasteride or finasteride
Study: NCT02608073
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
Study: NCT02785549
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/8hours
Study: NCT02785549
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/8 hours
Study: NCT00072709
Drug: TCH346
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02202759
Drug: MLN0264
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN0264 IV infusion
Study: NCT00000285
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00755183
Drug: testosterone ophthalmic solution
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: testosterone ophthalmic solution for 128 days
Study: NCT00755183
Drug: vehicle of testosterone ophthalmic solution
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vehicle of testosterone ophthalmic solution for 128 days
Study: NCT02937116
Drug: IBI308
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02937116
Drug: IBI308\Cisplatinum\Pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02937116
Drug: IBI308\cisplatin\gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02937116
Drug: IBI308\oxaliplatin\capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02937116
Drug: IBI308\etoposide\cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02937116
Drug: IBI308\irinotecan\5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00148317
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
Study: NCT00335777
Drug: Migranal nasal spray at 4 hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
Study: NCT00533208
Drug: MK0524
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00248404
Drug: NB1011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01667107
Drug: Calogen®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03536390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00936715
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/300 mg tablet administered orally once daily
Study: NCT04717310
Drug: SHR0302 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 Ointment Twice a day (BID)
Study: NCT04717310
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day (BID)
Study: NCT06323655
Drug: Active Control Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT00309374
Drug: LPS 2ng/kg intravenous bolus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00309374
Drug: Simvastatin 80mg; administered daily p.o. over 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00309374
Drug: Rosuvastatin 40mg; administered daily p.o. over 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01840241
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01725100
Drug: GSK1120212B (Standard DMSO content)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
Study: NCT02492763
Drug: MK-8521
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen \[60 μg, 120 μg\] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen \[60 μg, 120 μg, 180 μg\] over the first 3 weeks is used to achieve the final dose up to 300 μg.
Study: NCT02492763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
Study: NCT01394003
Drug: LY2584702
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT00716417
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
Study: NCT00716417
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: low to high dose, daily
Study: NCT02298582
Drug: intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
Study: NCT02885025
Drug: normal saline nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline to replace nasal fluticasone in specific arms of the study
Study: NCT04343248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally twice daily for six weeks
Study: NCT01320982
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: minocycline 100 mg/bid
Study: NCT01320982
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylsalicylic acid 500mg/ bid
Study: NCT01320982
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo bid
Study: NCT00461370
Drug: SRX251
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03968562
Drug: 2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
Study: NCT03774576
Drug: RO7017773
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of RO7017773
Study: NCT01746901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution + Placebo ALO-02 (intact)
Study: NCT01746901
Drug: intact ALO-02 60 mg/7.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution + ALO-02 60 mg/7.2 mg (intact)
Study: NCT01746901
Drug: crushed ALO-02 60 mg/7.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
Study: NCT01746901
Drug: crushed ALO-02 40 mg/4.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
Study: NCT04341870
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
Study: NCT00790842
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
Study: NCT04225897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle administered orally
Study: NCT00664625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, Once Daily, Single Dose
Study: NCT03622489
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mentioned above
Study: NCT03622489
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mentioned above
Study: NCT04668456
Drug: bupivacine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: subtenon injection
Study: NCT04668456
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: either subtenon or iv
Study: NCT02863419
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once-daily.
Study: NCT01208207
Drug: Part I - etoricoxib 60 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 60 mg oral tablet once daily for 6 weeks
Study: NCT01208207
Drug: Part I - etoricoxib 90 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 90 mg oral tablet once daily for 6 weeks
Study: NCT01208207
Drug: Part I- naproxen 1000 mg
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg oral tablet twice daily for 6 weeks
Study: NCT01208207
Drug: Part I - Placebo to naproxen 500 mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
Study: NCT01208207
Drug: Part II- etoricoxib 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 60 mg oral tablet once daily for 20 weeks
Study: NCT01208207
Drug: Part II- etoricoxib 90 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 90 mg oral tablet once daily for 20 weeks
Study: NCT01208207
Drug: Part II- naproxen 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg oral tablet twice daily for 20 weeks
Study: NCT01208207
Drug: Part I - Placebo to etoricoxib 60 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.